MedTrace Logo

Pharmacokinetic Study Comparing Aspirin and Effervescent Aspirin

NCT01081353 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2014-06-26

No results posted yet for this study

Summary

To determine the bioequivalence of new formula of aspirin relative to the established commercial effervescent aspirin when taken orally by healthy adult subjects

Conditions

  • Pharmacokinetics

Interventions

DRUG

Acetylsalicylic Acid (Aspirin BAY1019036)

One tablet of new formula Aspirin under fasting conditions

DRUG

Alka Seltzer Extra Strength

One effervescent tablet under fasting conditions

DRUG

Aspirin Migraine

One effervescent tablet under fasting conditions

DRUG

Aspirin Aspro

One effervescent tablet under fasting conditions

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01081353 on ClinicalTrials.gov